Xiaojun You

1.1k total citations
52 papers, 846 citations indexed

About

Xiaojun You is a scholar working on Pathology and Forensic Medicine, Rheumatology and Oncology. According to data from OpenAlex, Xiaojun You has authored 52 papers receiving a total of 846 indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Pathology and Forensic Medicine, 18 papers in Rheumatology and 14 papers in Oncology. Recurrent topics in Xiaojun You's work include Multiple Sclerosis Research Studies (34 papers), Rheumatoid Arthritis Research and Therapies (13 papers) and Polyomavirus and related diseases (12 papers). Xiaojun You is often cited by papers focused on Multiple Sclerosis Research Studies (34 papers), Rheumatoid Arthritis Research and Therapies (13 papers) and Polyomavirus and related diseases (12 papers). Xiaojun You collaborates with scholars based in United States, Germany and Switzerland. Xiaojun You's co-authors include Pamela Foulds, Robert Hyde, Richard A. Rudick, Elizabeth Fisher, Jack H. Simon, Robert Bermel, Serena Hung, Bernd C. Kieseier, Douglas L. Arnold and Dennis Bourdette and has published in prestigious journals such as The Journal of Immunology, PLoS ONE and Neurology.

In The Last Decade

Xiaojun You

51 papers receiving 825 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Xiaojun You United States	19	647	250	236	216	96	52	846
Deborah Dukovic United States	6	434 0.7×	139 0.6×	200 0.8×	210 1.0×	139 1.4×	17	755
E. Verdun Italy	14	843 1.3×	379 1.5×	437 1.9×	259 1.2×	148 1.5×	25	1.1k
Bénédicte Delcoigne Sweden	12	126 0.2×	256 1.0×	104 0.4×	89 0.4×	102 1.1×	45	554
Linda Carli Italy	16	228 0.4×	716 2.9×	70 0.3×	51 0.2×	366 3.8×	48	977
G. Castellino Italy	17	185 0.3×	623 2.5×	165 0.7×	33 0.2×	343 3.6×	32	934
Maurizio Bonfichi Italy	19	412 0.6×	59 0.2×	97 0.4×	282 1.3×	201 2.1×	54	1.1k
Jamal Mikdashi United States	11	147 0.2×	572 2.3×	167 0.7×	40 0.2×	280 2.9×	28	736
Akie Hirata Japan	8	295 0.5×	39 0.2×	53 0.2×	313 1.4×	180 1.9×	28	513
Enrica Cipriano Italy	16	103 0.2×	501 2.0×	70 0.3×	77 0.4×	275 2.9×	38	817
May Y. Choi Canada	16	155 0.2×	467 1.9×	59 0.3×	41 0.2×	303 3.2×	78	785

Countries citing papers authored by Xiaojun You

Since Specialization

Citations

This map shows the geographic impact of Xiaojun You's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaojun You with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaojun You more than expected).

Fields of papers citing papers by Xiaojun You

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaojun You. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaojun You. The network helps show where Xiaojun You may publish in the future.

Co-authorship network of co-authors of Xiaojun You

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaojun You. A scholar is included among the top collaborators of Xiaojun You based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaojun You. Xiaojun You is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chambost, Hérvè, Charles R. Hawes, Xiaojun You, et al.. (2024). Comparative Effectiveness of Valoctocogene Roxaparvovec and Prophylactic Factor VIII Replacement in Severe Hemophilia A. Advances in Therapy. 41(6). 2267–2281.

Astermark, Jan, Tyler W. Buckner, Laurent Frenzel, et al.. (2023). Matching‐adjusted indirect comparison of bleeding outcomes in severe haemophilia A: Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis. Haemophilia. 29(4). 1087–1094. 5 indexed citations

Wilson, John, Xiaojun You, Don S. Urquhart, et al.. (2020). VO2max as an exercise tolerance endpoint in people with cystic fibrosis: Lessons from a lumacaftor/ivacaftor trial. Journal of Cystic Fibrosis. 20(3). 499–505. 19 indexed citations

Schwarz, C., Sivagurunathan Sutharsan, Ralph Epaud, et al.. (2020). Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events. Journal of Cystic Fibrosis. 20(2). 228–233. 18 indexed citations

Zhang, Jixin, et al.. (2018). Incidence and risk factors for surgical site infection after open reduction and internal fixation of intra‐articular fractures of distal femur: A multicentre study. International Wound Journal. 16(2). 473–478. 20 indexed citations

Arnold, Douglas L., Xiaojun You, & Carmen Castrillo‐Viguera. (2017). Peginterferon beta-1a reduces the evolution of MRI lesions to black holes in patients with RRMS: a post hoc analysis from the ADVANCE study. Journal of Neurology. 264(8). 1728–1734. 3 indexed citations

Krueger, James G., Leon Kircik, Adam Friedman, et al.. (2016). Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis. Advances in Therapy. 33(7). 1231–1245. 26 indexed citations

Tolley, Keith, et al.. (2015). A Network Meta-Analysis of Efficacy and Evaluation of Safety of Subcutaneous Pegylated Interferon Beta-1a versus Other Injectable Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis. PLoS ONE. 10(6). e0127960–e0127960. 41 indexed citations

Newsome, Scott D., Songtao Guo, Arman Altincatal, et al.. (2015). Impact of peginterferon beta-1a and disease factors on quality of life in multiple sclerosis. Multiple Sclerosis and Related Disorders. 4(4). 350–357. 16 indexed citations

10.

Tolley, Keith, Michael Hutchinson, Andrew R. Pachner, et al.. (2014). Systematic Literature Review and Network Meta-Analysis of Pegylated Interferon Beta-1a and Disease Modifying Therapies for Relapsing-Remitting Multiple Sclerosis (P7.234). Neurology. 82(10_supplement). 1 indexed citations

11.

Hupperts, Raymond, V. Becker, Claudio Gobbi, et al.. (2014). Multiple sclerosis patients treated with intramuscular IFN-β-1a autoinjector in a real-world setting: prospective evaluation of treatment persistence, adherence, quality of life and satisfaction. Expert Opinion on Drug Delivery. 12(1). 15–25. 19 indexed citations

12.

Kieseier, Bernd C., Thomas F. Scott, Scott D. Newsome, et al.. (2014). Peginterferon Beta-1a May Improve Recovery Following Relapses: Data from the Pivotal Phase 3 ADVANCE Study in Patients with Relapsing-Remitting Multiple Sclerosis (S4.003). Neurology. 82(10_supplement). 1 indexed citations

13.

Scott, Thomas F., Genevieve Laforet, & Xiaojun You. (2013). Aggressive relapsing multiple sclerosis characterized by rapid disability progression. Multiple Sclerosis and Related Disorders. 2(4). 370–376. 3 indexed citations

14.

Wilken, Jeffrey, Robert L Kane, Mark Gudesblatt, et al.. (2013). Changes in Fatigue and Cognition in Patients with Relapsing Forms of Multiple Sclerosis Treated with Natalizumab. International Journal of MS Care. 15(3). 120–128. 33 indexed citations

15.

Scott, Thomas F., et al.. (2011). Functional system scores provide a window into disease activity occurring during a multiple sclerosis treatment trial. Neurological Research. 33(5). 549–552. 12 indexed citations

16.

Muller, Martin J., et al.. (2011). The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational study. BMC Neurology. 11(1). 144–144. 46 indexed citations

17.

Lampl, Christian, Xiaojun You, & Volker Limmroth. (2011). Weekly IM interferon beta‐1a in multiple sclerosis patients over 50 years of age. European Journal of Neurology. 19(1). 142–148. 10 indexed citations

18.

Rudick, Richard A., Jar-Chi Lee, Gary Cutter, et al.. (2010). Disability Progression in a Clinical Trial of Relapsing-Remitting Multiple Sclerosis. Archives of Neurology. 67(11). 1329–35. 55 indexed citations

19.

Bluebond‐Langner, Rachel, et al.. (2007). Does Fascia Lata Repair Facilitate Closure and Does It Affect Compartment Pressures of the Anterolateral Thigh Flap Donor Site?. Plastic & Reconstructive Surgery. 120(5). 1300–1304. 14 indexed citations

20.

Visvanathan, Kala, Rosa M. Crum, Paul T. Strickland, et al.. (2007). Alcohol Dehydrogenase Genetic Polymorphisms, Low‐to‐Moderate Alcohol Consumption, and Risk of Breast Cancer. Alcoholism Clinical and Experimental Research. 31(3). 467–476. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact